INDICATIONS

• Endometritis
• Peritonitis
• Septicemia
• Urinary Tract Infections
• Lower Respiratory Tract Infections

DOSAGE AND ADMINISTRATION

• Administration IV & IM
• Recommended dosage**
• Adults (50-90 kg): 150 mg every 12 h or 100 mg every 8 hour or 300 mg OD. (4-6mg/kg/day) Premature or full-term neonates, 1 week of age or less: 6 mg/kg daily in two divided doses. Neonates over 1 week of age and infants: 7.5-9.0 mg/kg daily in 3 divided doses.
• DUSAGE
• Children: 6.0-7.5 mg/kg daily in three divided doses.
• The duration of treatment is usually 12-14 days. In complicated infections, a longer course of theropy may be necessary. Patients treated beyond the usual period should be carefully monitored for changes in renal, auditory and vestibular function. Dosage should be reduced if clinically indicated.

AMINOGLYCOSIDE TOXICITY A REVIEW OF CLINICAL STUDIES'

TO DETERMINE THE PREVALENCE, CLINICAL EPIDEMIOLOGY AND ANTIMICROBIAL SUSCEPTIBILITY OF PSEUDOMONAS AERUGINOSA.

MATERIAL AND METHOD: Using WHONET data from 28 hospitals participating in the Natianal Antimicrobial Resistance Surveillance Thailand (NARST) program, all data were reviewed and analyzed for the prevalence, clinical epidemiology, and antimicrobial susceptibility of clinical isolates of P. aeruginosa from 2000 to 2005.

CLINICAL SAMPLE COLLECTED: Most common sites of isolation included sputum, pus, and urin.